Teva Kowa JV to target Japanese generics market
Teva and Kowa have set their sights on Japan’s $4.6bn (€3.1bn) generics market with their development and manufacturing joint venture Teva-Kowa Pharma.
Zentiva board accepts Sanofi’s revised €1.8bn offer
Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
Israeli court rules against “disingenuous” Taro
The Tel-Aviv District Court has found in favour of Sun Pharmaceuticals in its long running struggle to acquire Israeli drug and pharmaceutical ingredient maker Taro Pharmaceutical Industries.
Genentech rejects Roche but leaves door ajar
Genentech’s special advisory committee has rejected Roche’s $44bn offer for the biotech believing that it “substantially undervalues” the company.
APC parent to be bought by Otsuka Chemical
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.
MeadWestvaco and Bilcare jointly buy packaging firm
Contract packaging company International Labs has been taken over in a joint acquisition between India’s Bilcare and MeadWestvaco of the US.
Teva pounces on Barr with $7.5bn offer
There looks set to be further consolidation in the generics sector with Teva offering to acquire Barr Pharmaceuticals in a deal worth $7.5bn
Brookwood acquisition expands delivery portfolio
Brookwood Pharmaceuticals, a subsidiary of SurModics, has acquired the exclusive rights to all pharmaceutical applications of PharmaSol’s nanostructured lipid carrier (NLC) technology.
Sinclair and Wockhardt strike deal
UK-based Sinclair Pharmaceuticals has entered into a manufacturing
and distribution agreement with Wockhardt, an Indian pharmaceutical
and biotech company.
Pfizer to hijack Ranbaxy deal?
Pfizer may be poised to make a counter bid for Ranbaxy, potentially
scuppering the takeover by Daiichi which appeared to be a done
Daiichi to acquire majority stake in Ranbaxy
Japanese pharmaceutical firm Daiichi Sankyo is set to acquire a
majority stake in Ranbaxy Laboratories, in the biggest takeover
deal of an Indian pharmaceutical firm by an international company.
Biotech acquisitions scale new heights
Big pharma's lust for biotech's pipelines appears to be continuing
unabated with a record $27bn-worth of acquisitions and licensing
deals being made last year.
M&A movement in India with three top firms
Three of India´s large pharmaceutical manufacturers, Dr Reddy's,
Ranbaxy Laboratories and Shilpa Medicare have just announced new
merger and acquisition (M&A) deals.